Nuvectis Pharma, Inc. (NVCT)
NVCTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$21.00
0.0000 (0.00%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $722.17m
- P/E
- –
- EPS, last 4 quarters
- $-1.89
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.77 to $29.28
- Average volume
- –
- Previous close
- $21.00
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $34.50, +64.3% from here
Earnings
next estimate $-0.2600Next report
Dec 2025
-19.2%
Mar 2026
+13.3%
Jun 2026
-20.0%
Sep 2026
-363.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.62m | -$6.26m | -$7.20m | -$31.05m |
| Net income | -$7.31m | -$6.05m | -$7.02m | -$30.07m |
News
8 latest- Nuvectis Pharma Q3 Earnings Call HighlightsMarketBeat · Nov 4, 2026
- Nuvectis Pharma, Inc. Reports Third Quarter 2026 Financial Results and Business HighlightsFintel · Nov 4, 2026
- Nuvectis (NVCT) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 4, 2026
- Nuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent Gliomas RTTNews · Oct 26, 2026
- Nuvectis Stock Surges Around 97% in 3 Months: Here's WhyZacks · Aug 19, 2026
- Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should KnowZacks · Jul 29, 2026
- Nuvectis' Partner Haisco Wins NMPA Marketing Approval For Ciprocopan In Rare Blood Disorder RTTNews · Jul 23, 2026
- Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?Zacks · Jul 8, 2026
The company
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company's pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- nuvectis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.